Please enable JavaScript to continue using this application.

Compare $ABUS vs $ZYME | Chartloom

Compare

$ABUS vs $ZYME

Arbutus Biopharma Corp · Zymeworks Inc

ABUS

Arbutus Biopharma Corp

ZYME

Zymeworks Inc

Compare $ABUS vs $ZYME

Comparing Arbutus Biopharma Corp and Zymeworks Inc

ABUSArbutus Biopharma Corp

ZYMEZymeworks Inc

ABUSArbutus Biopharma Corp

Market cap

$834M

P/E (TTM)

5.44x

Forward P/E (NTM)

—

Forward P/S (NTM)

204.32x

Rev growth (TTM)

1078.8%

YTD performance

-11.5%

52W performance

1.0%

FCF yield

-3.0%

ZYMEZymeworks Inc

Market cap

$1.85B

P/E (TTM)

—

Forward P/E (NTM)

8.20x

Forward P/S (NTM)

3.91x

Rev growth (TTM)

-69.8%

YTD performance

-3.1%

52W performance

54.6%

FCF yield

-6.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ABUS

ZYME

Detailed metrics comparison

ABUS

Arbutus Biopharma Corp

ZYME

Zymeworks Inc

Market Cap

ABUS$834M

ZYME$1.85B

Enterprise Value

ABUS$818M

ZYME$1.92B

Price

ABUS$4.22

ZYME$25.79

P/E Ratio

ABUS5.44x

ZYMEN/A

P/S Ratio

ABUS4.59x

ZYME49.73x

EV/Sales

ABUS4.50x

ZYME51.70x

EV/EBITDA

ABUS4.98x

ZYME9.18x

P/B Ratio

ABUS3.41x

ZYME23.27x

P/FCF Ratio

ABUSN/A

ZYMEN/A

EV/FCF

ABUS-33.20x

ZYME-15.91x

PEG Ratio

ABUSN/A

ZYMEN/A

Forward P/E (NTM)

ABUSN/A

ZYME8.20x

Forward P/S (NTM)

ABUS204.32x

ZYME3.91x

Revenue (TTM)

ABUS$182M

ZYME$37M

Revenue Growth (YoY)

ABUS1078.8%

ZYME-69.8%

Forward Rev Growth

ABUS-97.7%

ZYME-15.2%

Gross Margin (TTM)

ABUS0.0%

ZYME0.0%

Operating Margin (TTM)

ABUS82.0%

ZYME0.0%

EBITDA Margin (TTM)

ABUS82.2%

ZYME-405.8%

Net Margin (TTM)

ABUS84.2%

ZYME-404.0%

FCF Margin (TTM)

ABUS-13.6%

ZYME-325.1%

Net Income (TTM)

ABUS$153M

ZYME$-150M

FCF (TTM)

ABUS$-25M

ZYME$-121M

EPS (TTM)

ABUS$0.78

ZYME-$2.05

ROE (TTM)

ABUS91.0%

ZYME-7207.0%

ROA (TTM)

ABUS82.3%

ZYME-3706.0%

ROIC (TTM)

ABUS89.2%

ZYME-4505.0%

Cash

ABUS$19M

ZYME$179M

Debt

ABUS$3M

ZYME$253M

Net Cash/Debt

ABUS$16M

ZYME$-73M

Current Ratio (TTM)

ABUS81.42x

ZYME6.32x

Quick Ratio (TTM)

ABUS80.97x

ZYME5.86x

Debt/Equity (TTM)

ABUS0.01x

ZYME3.14x

Debt/Assets (TTM)

ABUS0.0%

ZYME0.0%

Interest Coverage (TTM)

ABUSN/A

ZYMEN/A

Net Debt/EBITDA (TTM)

ABUS0.00x

ZYME0.00x

Beta

ABUS0.79

ZYME1.32

52W Performance

ABUS1.0%

ZYME54.6%

YTD Performance

ABUS-11.5%

ZYME-3.1%

% from 52W High

ABUS-22.6%

ZYME-17.7%

% from 52W Low

ABUS20.6%

ZYME61.2%

Asset Turnover (TTM)

ABUS0.98x

ZYME0.09x

FCF Yield (TTM)

ABUS-3.0%

ZYME-6.5%

Earnings Yield (TTM)

ABUS18.4%

ZYME-8.1%

Dividend Yield (TTM)

ABUSN/A

ZYMEN/A

Rule of 40

ABUS1,065.2

ZYME-394.8

EV/GP/RG

ABUSN/A

ZYMEN/A

Ticker research

View ABUS research View ZYME research

Metric	ABUS Arbutus Biopharma Corp	ZYME Zymeworks Inc
Market & Valuation
Market Cap	$834M	$1.85B
Enterprise Value	$818M	$1.92B
Price	$4.22	$25.79
P/E Ratio	5.44x	N/A
P/S Ratio	4.59x	49.73x
EV/Sales	4.50x	51.70x
EV/EBITDA	4.98x	9.18x
P/B Ratio	3.41x	23.27x
P/FCF Ratio	N/A	N/A
EV/FCF	-33.20x	-15.91x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	8.20x
Forward P/S (NTM)	204.32x	3.91x
Revenue & Growth
Revenue (TTM)	$182M	$37M
Revenue Growth (YoY)	1078.8%	-69.8%
Forward Rev Growth	-97.7%	-15.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	82.0%	0.0%
EBITDA Margin (TTM)	82.2%	-405.8%
Net Margin (TTM)	84.2%	-404.0%
FCF Margin (TTM)	-13.6%	-325.1%
Net Income (TTM)	$153M	$-150M
FCF (TTM)	$-25M	$-121M
EPS (TTM)	$0.78	-$2.05
ROE (TTM)	91.0%	-7207.0%
ROA (TTM)	82.3%	-3706.0%
ROIC (TTM)	89.2%	-4505.0%
Financial Health
Cash	$19M	$179M
Debt	$3M	$253M
Net Cash/Debt	$16M	$-73M
Current Ratio (TTM)	81.42x	6.32x
Quick Ratio (TTM)	80.97x	5.86x
Debt/Equity (TTM)	0.01x	3.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.79	1.32
52W Performance	1.0%	54.6%
YTD Performance	-11.5%	-3.1%
% from 52W High	-22.6%	-17.7%
% from 52W Low	20.6%	61.2%
Efficiency & Yields
Asset Turnover (TTM)	0.98x	0.09x
FCF Yield (TTM)	-3.0%	-6.5%
Earnings Yield (TTM)	18.4%	-8.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	1,065.2	-394.8
EV/GP/RG	N/A	N/A
Ticker research	View ABUS research	View ZYME research

Valuation

P/E Ratio

ABUS

5.44x

P/S Ratio

ABUS

4.59x

ZYME

49.73x

EV/FCF

ABUS

-33.20x

ZYME

-15.91x

Growth & revenue

Revenue Growth TTM

ABUS

1078.8%

ZYME

-69.8%

Forward Revenue Growth

ZYME

-15.2%

ABUS

-97.7%

Profitability & performance

Gross Margin

ABUS

0.0%

ZYME

0.0%

ROE

ABUS

91.0%

ZYME

-7207.0%

FCF Yield %

ABUS

-3.0%

ZYME

-6.5%

52-Week Performance

ZYME

54.6%

ABUS

1.0%

Detailed metrics comparison

ABUS

Arbutus Biopharma Corp

ZYME

Zymeworks Inc

Market Cap

ABUS$834M

ZYME$1.85B

Enterprise Value

ABUS$818M

ZYME$1.92B

Price

ABUS$4.22

ZYME$25.79

P/E Ratio

ABUS5.44x

ZYMEN/A

P/S Ratio

ABUS4.59x

ZYME49.73x

EV/Sales

ABUS4.50x

ZYME51.70x

EV/EBITDA

ABUS4.98x

ZYME9.18x

P/B Ratio

ABUS3.41x

ZYME23.27x

P/FCF Ratio

ABUSN/A

ZYMEN/A

EV/FCF

ABUS-33.20x

ZYME-15.91x

PEG Ratio

ABUSN/A

ZYMEN/A

Forward P/E (NTM)

ABUSN/A

ZYME8.20x

Forward P/S (NTM)

ABUS204.32x

ZYME3.91x

Revenue (TTM)

ABUS$182M

ZYME$37M

Revenue Growth (YoY)

ABUS1078.8%

ZYME-69.8%

Forward Rev Growth

ABUS-97.7%

ZYME-15.2%

Gross Margin (TTM)

ABUS0.0%

ZYME0.0%

Operating Margin (TTM)

ABUS82.0%

ZYME0.0%

EBITDA Margin (TTM)

ABUS82.2%

ZYME-405.8%

Net Margin (TTM)

ABUS84.2%

ZYME-404.0%

FCF Margin (TTM)

ABUS-13.6%

ZYME-325.1%

Net Income (TTM)

ABUS$153M

ZYME$-150M

FCF (TTM)

ABUS$-25M

ZYME$-121M

EPS (TTM)

ABUS$0.78

ZYME-$2.05

ROE (TTM)

ABUS91.0%

ZYME-7207.0%

ROA (TTM)

ABUS82.3%

ZYME-3706.0%

ROIC (TTM)

ABUS89.2%

ZYME-4505.0%

Cash

ABUS$19M

ZYME$179M

Debt

ABUS$3M

ZYME$253M

Net Cash/Debt

ABUS$16M

ZYME$-73M

Current Ratio (TTM)

ABUS81.42x

ZYME6.32x

Quick Ratio (TTM)

ABUS80.97x

ZYME5.86x

Debt/Equity (TTM)

ABUS0.01x

ZYME3.14x

Debt/Assets (TTM)

ABUS0.0%

ZYME0.0%

Interest Coverage (TTM)

ABUSN/A

ZYMEN/A

Net Debt/EBITDA (TTM)

ABUS0.00x

ZYME0.00x

Beta

ABUS0.79

ZYME1.32

52W Performance

ABUS1.0%

ZYME54.6%

YTD Performance

ABUS-11.5%

ZYME-3.1%

% from 52W High

ABUS-22.6%

ZYME-17.7%

% from 52W Low

ABUS20.6%

ZYME61.2%

Asset Turnover (TTM)

ABUS0.98x

ZYME0.09x

FCF Yield (TTM)

ABUS-3.0%

ZYME-6.5%

Earnings Yield (TTM)

ABUS18.4%

ZYME-8.1%

Dividend Yield (TTM)

ABUSN/A

ZYMEN/A

Rule of 40

ABUS1,065.2

ZYME-394.8

EV/GP/RG

ABUSN/A

ZYMEN/A

Ticker research

View ABUS research View ZYME research

Metric	ABUS Arbutus Biopharma Corp	ZYME Zymeworks Inc
Market & Valuation
Market Cap	$834M	$1.85B
Enterprise Value	$818M	$1.92B
Price	$4.22	$25.79
P/E Ratio	5.44x	N/A
P/S Ratio	4.59x	49.73x
EV/Sales	4.50x	51.70x
EV/EBITDA	4.98x	9.18x
P/B Ratio	3.41x	23.27x
P/FCF Ratio	N/A	N/A
EV/FCF	-33.20x	-15.91x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	8.20x
Forward P/S (NTM)	204.32x	3.91x
Revenue & Growth
Revenue (TTM)	$182M	$37M
Revenue Growth (YoY)	1078.8%	-69.8%
Forward Rev Growth	-97.7%	-15.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	82.0%	0.0%
EBITDA Margin (TTM)	82.2%	-405.8%
Net Margin (TTM)	84.2%	-404.0%
FCF Margin (TTM)	-13.6%	-325.1%
Net Income (TTM)	$153M	$-150M
FCF (TTM)	$-25M	$-121M
EPS (TTM)	$0.78	-$2.05
ROE (TTM)	91.0%	-7207.0%
ROA (TTM)	82.3%	-3706.0%
ROIC (TTM)	89.2%	-4505.0%
Financial Health
Cash	$19M	$179M
Debt	$3M	$253M
Net Cash/Debt	$16M	$-73M
Current Ratio (TTM)	81.42x	6.32x
Quick Ratio (TTM)	80.97x	5.86x
Debt/Equity (TTM)	0.01x	3.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.79	1.32
52W Performance	1.0%	54.6%
YTD Performance	-11.5%	-3.1%
% from 52W High	-22.6%	-17.7%
% from 52W Low	20.6%	61.2%
Efficiency & Yields
Asset Turnover (TTM)	0.98x	0.09x
FCF Yield (TTM)	-3.0%	-6.5%
Earnings Yield (TTM)	18.4%	-8.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	1,065.2	-394.8
EV/GP/RG	N/A	N/A
Ticker research	View ABUS research	View ZYME research